TransCode Therapeutics In... (RNAZ)
TransCode Therapeutics Statistics
Share Statistics
TransCode Therapeutics has 23.34M shares outstanding. The number of shares has increased by 256.81% in one year.
| Shares Outstanding | 23.34M |
| Shares Change (YoY) | 256.81% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.09% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 400 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.04M, so 4.45% of the outstanding shares have been sold short.
| Short Interest | 1.04M |
| Short % of Shares Out | 4.45% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -0.01 |
| PS Ratio | 0 |
| Forward PS | 1.3 |
| PB Ratio | -0.01 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of -0.02.
| Current Ratio | 2.56 |
| Quick Ratio | 2.56 |
| Debt / Equity | -0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -584.07 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,397,938.86 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -3.99% in the last 52 weeks. The beta is 1.52, so TransCode Therapeutics's price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | -3.99% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 67.15 |
| Average Volume (20 Days) | 7,262,462 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.66M |
| Net Income | -16.79M |
| EBITDA | -14.03M |
| EBIT | -14.57M |
| Earnings Per Share (EPS) | -47.14 |
Balance Sheet
The company has 5.81M in cash and 38.29K in debt, giving a net cash position of 5.77M.
| Cash & Cash Equivalents | 5.81M |
| Total Debt | 38.29K |
| Net Cash | 5.77M |
| Retained Earnings | -63.2M |
| Total Assets | 7.29M |
| Working Capital | 4.32M |
Cash Flow
In the last 12 months, operating cash flow was -13.34M and capital expenditures 0, giving a free cash flow of -13.34M.
| Operating Cash Flow | -13.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | -13.34M |
| FCF Per Share | -37.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RNAZ is $10, which is 1685.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 1685.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 4, 2024. It was a backward split with a ratio of 1:33.
| Last Split Date | Dec 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:33 |
Scores
| Altman Z-Score | -18.35 |
| Piotroski F-Score | 2 |